Literature DB >> 26675004

Colorectal Cancer: Basic and Translational Research.

J J Zhou1, S Zheng1.   

Abstract

BACKGROUND: Colorectal cancer (CRC) still accounts for high mortality and morbidity of cancer patients worldwide. Early detection screening and therapeutic management of CRC are still traditional, with some important progress including cetuximab, microsatellite instability and the concept of CRC intrinsic subtypes.
SUMMARY: Most achievements are derived from translational cancer research. Translational cancer research attempts to better understand the heterogeneity of human cancer and further turn discoveries into benefits for cancer patients. The four basic strategies of translational research can be depicted as (a) biomarker discovery, (b) identification in xenografts, (c) population-based verification and (d) clinical validation.

Entities:  

Keywords:  Colorectal neoplasms; Therapeutics; Translational medical research

Year:  2013        PMID: 26675004      PMCID: PMC4645573          DOI: 10.1159/000354994

Source DB:  PubMed          Journal:  Gastrointest Tumors        ISSN: 2296-3774


  29 in total

1.  Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30.

Authors:  P M Fayers
Journal:  Eur J Cancer       Date:  2001-07       Impact factor: 9.162

2.  Translating research into clinical practice: deliberations from the American Association for Cancer Research.

Authors:  William N Hait
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

3.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

4.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy.

Authors:  Anguraj Sadanandam; Costas A Lyssiotis; Krisztian Homicsko; Eric A Collisson; William J Gibb; Stephan Wullschleger; Liliane C Gonzalez Ostos; William A Lannon; Carsten Grotzinger; Maguy Del Rio; Benoit Lhermitte; Adam B Olshen; Bertram Wiedenmann; Lewis C Cantley; Joe W Gray; Douglas Hanahan
Journal:  Nat Med       Date:  2013-04-14       Impact factor: 53.440

5.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Authors:  Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

Review 6.  Targeted therapy of cancer: new roles for pathologists in colorectal cancer.

Authors:  Stanley R Hamilton
Journal:  Mod Pathol       Date:  2008-05       Impact factor: 7.842

Review 7.  KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.

Authors:  Antonio Jimeno; Wells A Messersmith; Fred R Hirsch; Wilbur A Franklin; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

8.  Comprehensive molecular characterization of human colon and rectal cancer.

Authors: 
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962

9.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

Authors:  F Di Fiore; F Blanchard; F Charbonnier; F Le Pessot; A Lamy; M P Galais; L Bastit; A Killian; R Sesboüé; J J Tuech; A M Queuniet; B Paillot; J C Sabourin; F Michot; P Michel; T Frebourg
Journal:  Br J Cancer       Date:  2007-03-20       Impact factor: 7.640

10.  Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.

Authors:  Xiyong Liu; Hang Zhang; Lily Lai; Xiaochen Wang; Sofia Loera; Lijun Xue; Huiyin He; Keqiang Zhang; Shuya Hu; Yasheng Huang; Rebecca A Nelson; Bingsen Zhou; Lun Zhou; Peiguo Chu; Suzhan Zhang; Shu Zheng; Yun Yen
Journal:  Clin Sci (Lond)       Date:  2013-05       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.